Purolite today announces that its Praesto agarose-based Protein A and Ion Exchange chromatography resins will be made available in South Korea and Singapore. Purolite will offer these products through an enhanced strategic partnership with PharmNXT Biotech, who provide solutions to Pharma and broader Life Sciences markets.

Praesto resins are an integral technology used by biopharmaceutical developers for the purification of modern medicines for the treatment of cancer, rheumatoid arthritis, dementia and diabetes. Praesto Jetted A50, launched in April 2018 is Purolite's 'best-in-class' Protein A chromatography resin, utilizing a patented, 'Jetting' manufacturing technology for uniform resin beads, a highly desirable characteristic for chromatographic applications.

Chris Major, Global Sales and Marketing Director for Praesto, comments, "We are delighted to extend our partnership with PharmNXT Biotech LLP for the supply, distribution and application support of the Praesto range in South Korea". He continued, "they have a strong presence in Asia, and are a dynamic organization, ideally placed to support our customers. Improving our presence in Asia further only complements our recent expansion to offer manufacturing sites in both Europe and the USA, ensuring global availability of advanced resin products at short lead times. We look forward to continuing to meet customer requirements for improved security of supply, reduced lead times and high-performance of modern Protein A resins."

Ankush Kapoor, CEO of PharmNXT Biotech says, "We are really excited to represent Purolite resins to other markets of Asia". Sachin Joshi, Managing Director of PharmNXT Biotech continued saying "This partnership with Purolite offers customers in South Korea and Singapore access to best-in-class agarose chromatography resins for Monoclonal Antibody, Vaccine and Recombinant protein purification." he continued, "We are continually impressed by Purolite's commitment to global security of supply through their continued investments and state-of-the-art facilities in the UK and USA."